Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Microparticle-based technologies for vaccines.

Derek T O'Hagan1, Manmohan Singh, Jeffrey B Ulmer

  • 1Vaccines Research, Novartis Vaccines and Diagnostics, Inc., 4560 Horton Street, Mail Stop 4.3, Emeryville, CA 94608, USA.

Methods (San Diego, Calif.)
|September 26, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Insights into Persistent SARS-CoV-2 Reservoirs in Chronic Long COVID.

Viruses·2025
Same author

A Multi-Antigen Broad-Spectrum Coronavirus Vaccine Induces Potent and Durable Cross-Protection Against Infection and Disease Caused by Multiple SARS-CoV-2 Variants.

Research square·2025
Same author

A pan-beta-coronavirus vaccine bearing conserved and asymptomatic B- and T-cell epitopes protects against highly pathogenic Delta and highly transmissible Omicron SARS-CoV-2 variants.

Human vaccines & immunotherapeutics·2025
Same author

Dynamics of spike-specific neutralizing antibodies across five-year emerging SARS-CoV-2 variants of concern reveal conserved epitopes that protect against severe COVID-19.

Frontiers in immunology·2025
Same author

Antigen Delivery Platforms for Next-Generation Coronavirus Vaccines.

Vaccines·2025
Same author

Microfluidic-Chip-Based Formulation and In Vivo Evaluations of Squalene Oil Emulsion Adjuvants for Subunit Vaccines.

Vaccines·2025
Same journal

EC-isHCR: A rapid method for in situ hybridization chain reaction in diverse animal samples.

Methods (San Diego, Calif.)·2026
Same journal

Single-Molecule methods to investigate mechanisms of transcription by RNA polymerase of Mycobacterium tuberculosis.

Methods (San Diego, Calif.)·2026
Same journal

Detection and sequencing of Usutu virus during mosquito surveillance: Use of multiple assays and techniques for identification at low levels.

Methods (San Diego, Calif.)·2026
Same journal

Experimental validation of an AI-driven digital healthcare platform for oral health behavior and plaque assessment among vietnamese children.

Methods (San Diego, Calif.)·2026
Same journal

Zeta potential: An efficient and cost-effective alternative for investigating cell-surface interactions.

Methods (San Diego, Calif.)·2026
Same journal

An automated workflow for quantifying the formation of synuclein aggregates in human dopaminergic neurons.

Methods (San Diego, Calif.)·2026
See all related articles

Microparticle delivery systems show excellent potential for vaccines, enhancing immune responses when combined with immune potentiators. This technology is expanding for various vaccine types, offering potent results.

Area of Science:

  • Biotechnology
  • Immunology
  • Materials Science

Background:

  • Microparticles are established drug and protein delivery systems.
  • Vaccine delivery via microparticles is an emerging and growing field.
  • Microparticles can deliver various vaccine components, including recombinant proteins, DNA, and peptides.

Purpose of the Study:

  • To explore the utility of microparticles for vaccine delivery.
  • To investigate the synergistic effects of microparticle-delivered immune potentiators.
  • To assess the potential for broad application of microparticle-based vaccine delivery systems.

Main Methods:

  • Review of existing literature on microparticle-based delivery systems.
  • Analysis of studies demonstrating microparticle utility for different vaccine types.

Related Experiment Videos

  • Examination of immune responses elicited by combined vaccine components delivered via microparticles.

    • Main Results:

    • Microparticles have proven effective for delivering recombinant proteins, plasmid DNA, and peptides.
    • Synergistic immune responses are observed when immune potentiators are co-delivered with vaccine antigens using microparticles.
    • The combination of microparticle delivery and immune potentiators leads to significantly more potent immune responses.

    Conclusions:

    • Microparticle-based delivery systems offer excellent prospects for broad vaccine application.
    • The synergistic effects observed highlight the potential for enhanced vaccine efficacy.
    • Further development in this area is warranted for next-generation vaccines.